logo-loader
viewPuma Biotechnology Inc

Puma Biotechnology shares rocket after biopharma zips past Street's 4Q estimate

Puma won approval from the FDA for Nerlynx, which treats early-stage HER2-positive breast cancer, in July of 2017

cancer in headline
Revenue from Nerlynx accounted for the bulk of the $71.1 million in sales Puma reported in the fourth quarter

Shares of Puma Biotechnology (NASDAQ:PBYI) rocketed Friday after the biopharmaceutical company beat Wall Street’s fourth-quarter estimates thanks to sales of its flagship breast cancer drug Nerlynx (neratinib).

In its latest reporting period, the Los Angeles company’s net loss shrank to $12.2 million, or $0.32 per share, from a loss of $38.6 million, or $1.03 per share, in the year-ago quarter. Its sales amounted to $71.1 million, of which $61.1 million was revenue from Nerlynx and $10 million was license revenue.

Investors were impressed by the results, sending Puma shares up 28% to $35.60 in pre-market action before Friday’s opening bell.

READ: Puma Biotechnology’s 3Q earnings beat Street, but stock plummets as sale of cancer drug Nerlynx slows

Analysts had expected Puma to lose $0.69 and post revenue of $53.65 million.

Puma won approval from the US Food and Drug Administration for Nerlynx which treats early-stage HER2-positive breast cancer, in July of 2017. The drug has also been granted marketing authorization to treat early-stage breast cancer by the European Commission.

Contact Ellen [email protected]

Quick facts: Puma Biotechnology Inc

Price: 10.59 USD

NASDAQ:PBYI
Market: NASDAQ
Market Cap: $416.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: PetVivo preparing to bring their lead medical device Kush to...

PetVivo (OTCQB: PETV) CEO John Lai joined Steve Darling from Proactive to discuss the company that is developing a treatment for osteoarthritis is horses and dogs. The company’s lead medical device is called Kush and according to PetVivo it mimics cartilage. Lai tells Proactive about the size...

5 hours, 36 minutes ago

2 min read